ArcticZymes Technologies launches SAN HQ 2.0 ELISA kit

Tromsø, Norway, 20^th December 2022 – ArcticZymes Technologies ASA (OSE: AZT) announces the launch of SAN HQ 2.0 ELISA kit

ArcticZymes Technologies (AZT) announces the launch of the SAN HQ 2.0 ELISA kit.

The SAN HQ 2.0 ELISA kit is intended as a natural companion product to our already successful Salt Active Nuclease – SAN HQ 2.0. The new ELISA product is a classic sandwich immunoassay designed to detect and quantify the presence of the SAN HQ 2.0 nuclease at trace amounts.

Customers working with bioprocessing workflows will be able to use SAN HQ 2.0 to remove contaminating nucleic acids, and then verify the removal of the nuclease using the SAN HQ 2.0 ELISA kit after downstream processing and purification.

This is important as all processing agents, used during biomanufacturing processes leading to human therapeutic agents, are subject to tight controls with respect to residual amounts present in the final formulation. Quantification is critical, therefore the enzyme SAN HQ 2.0 and the new SAN HQ 2.0 ELISA kit are complementary products. The new ELISA kit will further accelerate the adoption of SAN HQ 2.0 in our customers’ bioprocessing workflows.

The global biomanufacturing market has seen significant growth in recent years, in part due to a boom in cell and gene therapy development, and the high demand for vaccine manufacturing during the Coronavirus pandemic. Providing our customers with more complete solutions, such as processing enzymes and corresponding immunoassay kits, will be an important driver to continued sales growth in the biomanufacturing business.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"We are excited to announce the successful launch of the SAN HQ 2.0 ELISA kit. It further extends the relevance of our SAN portfolio in the biomanufacturing market.”

For more information, please contact:

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies’ IP and capabilities are protected via a large portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.